Canadian Cancer Trials Group Bulletins

Trial Management Group

Canadian Cancer Trials Group MY.10 Permanently Closed

Canadian Cancer Trials Group MY.10 -- A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma -- has been permanently closed and no longer requires action, including patient follow-up for trial purposes, completion of Case Report Forms and annual REB re-approvals.

A memo has been posted to the Canadian Cancer Trials Group MY.10 trial-specific website.

The final analysis for this trial was done in July 2010 and results were published online in Blood in January 2013. The authors reported that maintenance therapy with thalidomide-prednisone following autologous stem cell transplant improves the duration of disease control, but is associated with worsening of patient-reported HRQoL and no detectable overall survival benefit.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) with a quality of life assessment: Canadian Cancer Trials Group MY.10 Trial (ONLINE). Blood 2013.

Please note that as of September 19, 2013, any documentation submitted to Canadian Cancer Trials Group for this trial will not be accepted and will be returned to sites.